IL17A and psoriasis vulgaris: Notably, the anti-IL-17A monoclonal antibody vunakizumab has been approved for treating moderate-to-severe plaque psoriasis.41 Whether vunakizumab combined with NAT can improve pCR rates in EAscore-low patients warrants further investigation.